Keyword: Alexion Pharmaceuticals
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics.
The rejig sees Alexion scrapping deals with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma as it seeks to focus its R&D.
It’s not been a great six months for the leadership of Alexion as a sales scandal has forced a series of major changes at the top of the organization; one of these was Martin Mackay, who will “retire” this year, and will now be replaced by John Orloff, M.D.
Alexion Pharmaceuticals is set to lay off 7% of its staff and scrap some R&D programs to restructure its business following a tricky period.